Predicted protein targets (top 8)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | DUT | P33316 | 2/20 | 0.47 |
| ▸ | KMT2A | Q03164 | 3/20 | 0.34 |
| ▸ | MEN1 | O00255 | 2/20 | 0.34 |
| ▸ | POLB | P06746 | 1/20 | 0.34 |
| ▸ | KDM4E | B2RXH2 | 2/20 | 0.34 |
| ▸ | HTT | P42858 | 1/20 | 0.34 |
| ▸ | LMNA | P02545 | 1/20 | 0.31 |
| ▸ | GAA | P10253 | 1/20 | 0.31 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL19335630 | 0.81 | DUT (0.50) | DUTKMT2AMEN1POLBKDM4E | |
| SCHEMBL22748850 | 0.72 | DUT (0.42) | DUTKMT2AMEN1KDM4EHTT | |
| SCHEMBL23174829 | 0.72 | DUT (0.43) | DUT | |
| SCHEMBL7576935 | 0.69 | KMT2A (0.54) | DUTKMT2AMEN1POLBKDM4E | |
| SCHEMBL27032644 | 0.69 | DUT (0.43) | DUTKMT2AMEN1POLB | |
| SCHEMBL28881510 | 0.68 | DUT (0.44) | DUTKMT2AMEN1HTTLMNA | |
| SCHEMBL10308261 | 0.68 | NPC1 (0.33) | POLBKDM4EHTTLMNA | |
| SCHEMBL22748851 | 0.68 | DUT (0.40) | DUTKMT2AMEN1KDM4EHTT | |
| SCHEMBL25744924 | 0.66 | PDE2A (0.30) | — | |
| SCHEMBL9752777 | 0.66 | CA2 (0.43) | DUT |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-9758509-B2 | Substituted 3-(5-membered unsaturated heterocyclyl-1, 3-dihydro-indol-2-one's and derivatives thereof as kinase inhibitors | ALLERGAN, INC. (US) | 2017-09-12 | — | — | US | disclosed |
| US-20170174664-A1 | SUBSTITUTED 3-(5-MEMBERED UNSATURATED HETEROCYCLYL-1, 3-DIHYDRO-INDOL-2-ONE'S AND DERIVATIVES THEREOF AS KINASE INHIBITORS | ALLERGAN, INC. | 2017-06-22 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20170174664-A1 | SUBSTITUTED 3-(5-MEMBERED UNSATURATED HETEROCYCLYL-1, 3-DIHYDRO-INDOL-2-ONE'S AND DERIVATIVES THEREOF AS KINASE INHIBITORS | DSTYK, CDK2, ERBB2 | DUT 860/4885KMT2A 1867/4885MEN1 3146/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.